Filing Details
- Accession Number:
- 0001209191-14-067900
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-11-12 11:50:58
- Reporting Period:
- 2014-11-12
- Filing Date:
- 2014-11-12
- Accepted Time:
- 2014-11-12 11:50:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1512762 | Coherus Biosciences Inc. | CHRS | Biological Products, (No Disgnostic Substances) (2836) | 273615821 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 59478 | Lilly Eli & Co | Lilly Corporate Center Indianapolis IN 46285 | No | No | No | Yes | |
| 1575852 | Lilly Ventures Fund I Llc | C/O Coherus Biosciences, Inc. 201 Redwood Shores Parkway Suite 200 Redwood City CA 94065 | No | No | No | Yes |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 Par Value | Acquisiton | 2014-11-12 | 2,333,955 | $0.00 | 2,333,955 | No | 4 | C | Direct | |
| Common Stock, $0.0001 Par Value | Acquisiton | 2014-11-12 | 543,101 | $0.00 | 2,877,056 | No | 4 | C | Direct | |
| Common Stock, $0.0001 Par Value | Acquisiton | 2014-11-12 | 164,963 | $13.50 | 3,042,019 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series B Preferred Stock | Disposition | 2014-11-12 | 2,333,955 | $0.00 | 2,333,955 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2014-11-12 | 543,101 | $0.00 | 543,101 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1-for-1 basis upon the closing of Issuer's initial public offering.
- These shares are owned directly by Lilly Ventures Fund I LLC (the "Fund"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund.
- Lilly Ventures Fund I LLC purchased an additional 164,963 shares of Issuer's Common Stock in connection with the IPO at the offering price of $13.50 per share.
- The Series B Preferred Stock and Series C Preferred Stock have no expiration date.
Billionaire Hedge Funds
